Dr. Miguel Islas-Ohlmayer
Claim this profileOncology Hematology Care
Studies Lymphoma
Studies B-Cell Lymphoma
6 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
CD30 negative
HTLV-1 positive
2B-Cell Lymphoma
Affiliated Hospitals
Clinical Trials Miguel Islas-Ohlmayer is currently running
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting1 award Phase 34 criteria
Pirtobrutinib
for Chronic Lymphocytic Leukemia
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Recruiting1 award Phase 26 criteria
More about Miguel Islas-Ohlmayer
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Miguel Islas-Ohlmayer has experience with
- Rituximab
- Brentuximab Vedotin
- Doxorubicin
- LOXO-305
- Lenalidomide
- Tazemetostat
Breakdown of trials Miguel Islas-Ohlmayer has run
Lymphoma
Childhood Blood Disease
Mixed-Cell Lymphoma
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Miguel Islas-Ohlmayer specialize in?
Miguel Islas-Ohlmayer focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD30 negative patients, or patients who are HTLV-1 positive.
Is Miguel Islas-Ohlmayer currently recruiting for clinical trials?
Yes, Miguel Islas-Ohlmayer is currently recruiting for 2 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Miguel Islas-Ohlmayer has studied deeply?
Yes, Miguel Islas-Ohlmayer has studied treatments such as Rituximab, Brentuximab Vedotin, Doxorubicin.
What is the best way to schedule an appointment with Miguel Islas-Ohlmayer?
Apply for one of the trials that Miguel Islas-Ohlmayer is conducting.
What is the office address of Miguel Islas-Ohlmayer?
The office of Miguel Islas-Ohlmayer is located at: Oncology Hematology Care, Cincinnati, Ohio 45242 United States. This is the address for their practice at the Oncology Hematology Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.